DE69835167T8 - 1,2,4-benzotriazin-oxide enthaltende zubereitungen - Google Patents

1,2,4-benzotriazin-oxide enthaltende zubereitungen Download PDF

Info

Publication number
DE69835167T8
DE69835167T8 DE69835167T DE69835167T DE69835167T8 DE 69835167 T8 DE69835167 T8 DE 69835167T8 DE 69835167 T DE69835167 T DE 69835167T DE 69835167 T DE69835167 T DE 69835167T DE 69835167 T8 DE69835167 T8 DE 69835167T8
Authority
DE
Germany
Prior art keywords
oxide containing
containing preparations
benzotriazine oxide
benzotriazine
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69835167T
Other languages
German (de)
English (en)
Other versions
DE69835167T2 (de
DE69835167D1 (de
Inventor
Stephen Brown
Edward Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis US LLC
Original Assignee
Sanofi Aventis US LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis US LLC filed Critical Sanofi Aventis US LLC
Application granted granted Critical
Publication of DE69835167D1 publication Critical patent/DE69835167D1/de
Publication of DE69835167T2 publication Critical patent/DE69835167T2/de
Publication of DE69835167T8 publication Critical patent/DE69835167T8/de
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
DE69835167T 1997-04-21 1998-04-14 1,2,4-benzotriazin-oxide enthaltende zubereitungen Expired - Fee Related DE69835167T8 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US837637 1997-04-21
US08/837,637 US5827850A (en) 1995-09-25 1997-04-21 1,2,4-benzotriazine oxides formulations
PCT/US1998/007391 WO1998047512A1 (en) 1997-04-21 1998-04-14 1,2,4-benzotriazine oxides formulations

Publications (3)

Publication Number Publication Date
DE69835167D1 DE69835167D1 (de) 2006-08-17
DE69835167T2 DE69835167T2 (de) 2007-06-06
DE69835167T8 true DE69835167T8 (de) 2007-12-06

Family

ID=25275027

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69835167T Expired - Fee Related DE69835167T8 (de) 1997-04-21 1998-04-14 1,2,4-benzotriazin-oxide enthaltende zubereitungen

Country Status (13)

Country Link
US (2) US5827850A (https=)
EP (1) EP1044005B1 (https=)
JP (1) JP2001523248A (https=)
AT (1) ATE332139T1 (https=)
AU (1) AU6969098A (https=)
BR (1) BR9808958A (https=)
CA (1) CA2287257C (https=)
DE (1) DE69835167T8 (https=)
DK (1) DK1044005T3 (https=)
ES (1) ES2267183T3 (https=)
NO (1) NO325275B1 (https=)
PT (1) PT1044005E (https=)
WO (1) WO1998047512A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624925A (en) * 1986-09-25 1997-04-29 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
NZ521436A (en) * 2002-09-17 2005-07-29 Auckland Uniservices Ltd DNA- targeted benzotriazine 1,4-dioxides and their use in cancer therapy
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
CA2456569A1 (en) * 2003-03-14 2004-09-14 Auckland Uniservices Limited Benzoazine mono-n-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
US7834178B2 (en) * 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
CN101683346B (zh) * 2008-09-24 2015-04-01 杭州民生药业有限公司 一种替拉扎明非肠道含水制剂及其制备方法
CN101683319B (zh) * 2008-09-24 2012-09-05 杭州民生药业有限公司 一种替拉扎明非肠道给药含水制剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980779A (en) * 1972-02-01 1976-09-14 Bayer Aktiengesellschaft 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxide compositions and method of using same
US4001410A (en) * 1972-02-01 1977-01-04 Bayer Aktiengesellschaft 3-amino-1,2,4-benzotriazine-1,4-di-n-oxide compositions and method of using same
US5175287A (en) * 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
DE69636837T2 (de) * 1995-09-25 2007-10-25 Sanofi-Aventis U.S. Llc 1,2,4-benzotriazinoxid-formulierungen

Also Published As

Publication number Publication date
PT1044005E (pt) 2006-10-31
EP1044005A4 (en) 2001-08-08
ATE332139T1 (de) 2006-07-15
CA2287257A1 (en) 1998-10-29
DK1044005T3 (da) 2006-09-25
CA2287257C (en) 2007-06-12
WO1998047512A1 (en) 1998-10-29
EP1044005A1 (en) 2000-10-18
US5827850A (en) 1998-10-27
US6153610A (en) 2000-11-28
BR9808958A (pt) 2000-08-01
DE69835167T2 (de) 2007-06-06
ES2267183T3 (es) 2007-03-01
AU6969098A (en) 1998-11-13
EP1044005B1 (en) 2006-07-05
NO325275B1 (no) 2008-03-17
DE69835167D1 (de) 2006-08-17
NO995109D0 (no) 1999-10-20
JP2001523248A (ja) 2001-11-20
NO995109L (no) 1999-12-21

Similar Documents

Publication Publication Date Title
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
HU9301314D0 (en) Quinazoline derivatves for improving anto-tumouric activity
ZA921911B (en) 2,4-diaminoquinazoline derivatives for enhancing anti-tumor activity.
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
IL145381A0 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
NO985574L (no) FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
AU2002305099A1 (en) Fatty alcohol drug conjugates
DE60041333D1 (de) Hen prostatkrebs exprimiert wird, und deren verwendungen
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
NO20015516D0 (no) Preparater og anvendelser av ET743 for behandling av kreft
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
TR200001147T2 (tr) Kanser ve makular dejenerasyonun tedavisi için makrolidlerin kullanımı
DE69835167D1 (de) 1,2,4-benzotriazin-oxide enthaltende zubereitungen
DK0972782T3 (da) Monoklonalt antistof, der genkender oligosaccharidet N-glycolyleret galactose-glucose-sialinsyre i maligne tumorer, og præparater, der indeholder det
MY137303A (en) Methods for treating proliferative diseases
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
EP1364657A4 (en) AGAINST TUMORS IN HEMATOPOETIC ORGANS
ZA982136B (en) Novel carboxylic acid derivatives, their preparation and use in treating cancer.
CA2232989A1 (en) 1,2,4-benzotriazine oxides formulations
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
SE0100684D0 (sv) New subject-matter

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS U.S. LLC, BRIDGEWATER, N.J., US

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC

8339 Ceased/non-payment of the annual fee